

March 09, 2026

**To,**  
**BSE Limited**  
**Phiroze Jeejeebhoy Towers,**  
**Dalal Street, Mumbai – 400001**  
**Scrip Code: 532372**

**To,**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra-Kurla Complex,**  
**Bandra (E), Mumbai - 400051**  
**Symbol: VIRINCHI**

Dear Sir/Madam,

**Subject : Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) read with Part A of Schedule III thereof, we hereby inform you that pursuant to:

- Postal Ballot resolutions passed by the shareholders of M/s. Virinchi Limited on February 23, 2026, (i) Approval for investment by a related party in M/S. Virinchi Health Care Private Limited, 100% subsidiary of Virinchi Limited, and (ii) To approve the issue of Convertible Equity Warrants by M/s. Virinchi Health Care Private Limited, 100% subsidiary of Virinchi Limited; and
- Special Resolution passed by the shareholders of M/s. Virinchi Health Care Private Limited on February 25, 2026, (i) Issue of Convertible Equity Warrants to certain identified Promoter on preferential basis;

the Board of Directors of M/s. Virinchi Health Care Private Limited at its meeting held on March 03, 2026 allotted 52,22,000 Convertible Equity Warrants to Viswanath Kompella, Promoter of the Company, on a preferential basis. Each Convertible Equity Warrant entitles the holder to subscribe for one equity share of M/s. Virinchi Health Care Private Limited upon exercise of the conversion right.

Pursuant to the exercise of conversion rights, each of the aforesaid Convertible Equity Warrants was converted into one fully paid-up equity share of M/s. Virinchi Health Care Private Limited on the following dates: 48,85,000 warrants were converted into 48,85,000 equity shares on March 05, 2026, and the remaining 3,37,000 warrants were converted into 3,37,000 equity shares on March 09, 2026, resulting in a total allotment of 52,22,000 equity shares to Mr. Viswanath Kompella.

Consequently, Virinchi Health Care Private Limited has ceased to be a wholly-owned subsidiary of the Company and continues to remain a subsidiary of the Company in terms of the provisions of the Companies Act, 2013 and the SEBI Listing Regulations.

Share holding pattern of M/s. Virinchi Health Care Private Limited before and after aforementioned allotment:

S.No.	Shareholder name	Shares (Before)	% (Before)	Shares (After)	% (After)
1	M/s. Virinchi Limited	54,35,978	100	54,35,978	51
2	Mr. Viswanath Kompella	-	-	52,22,000	49
<b>Total</b>		<b>54,35,978</b>	<b>100</b>	<b>1,06,57,978</b>	<b>100</b>

The required disclosure, as per Regulation 30 read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155, is enclosed herewith as **Annexure I**.

This intimation is being submitted to the Stock Exchanges for your information and record in compliance with Regulation 30 of the SEBI Listing Regulations.

Thanking you,

Yours faithfully,

**For Virinchi Limited**

**K. Ravindranath Tagore**  
**Company Secretary**  
**M.No.A18894**

Encl. as above

**Annexure I**

S.No.	Particulars	Information
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Turnover of VHPL for the year 2024-25: Rs. 92,54,07,362/- Percentage of Consolidated Turnover: 30.73% Networth: Rs. (93,12,421)/- Percentage of Consolidated Networth: Not applicable
2.	Date on which the agreement for sale has been entered into;	Not Applicable – No sale agreement executed. The change in status occurred due to allotment of equity shares upon conversion of convertible equity warrants (on a 1:1 basis, i.e., each warrant converted into one equity share) issued on preferential basis.
3.	The expected date of completion of sale/disposal;	Not Applicable – Transaction completed upon conversion of convertible equity warrants into equity shares: 48,85,000 warrants converted into equity shares on March 05, 2026, and the remaining 3,37,000 warrants converted into equity shares on March 09, 2026.
4.	Consideration received from such sale/disposal;	Total consideration received: Rs. 7,83,30,000/- (being 52,22,000 convertible equity warrants issued at Rs.15/- per warrant, each of which has been converted into one equity share of M/s. Virinchi Health Care Private Limited on a 1:1 basis).  The preferential allotment has been made based on the enterprise valuation of M/s. Virinchi Health Care Private Limited at <b>Rs. 312.08 Crore</b> , as determined in accordance with the valuation report issued by an independent registered valuer.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Mr. Viswanath Kompella, Promoter of the Company, was allotted 52,22,000 equity shares of Virinchi Health Care Private Limited at Rs.15/- per share upon conversion of convertible equity warrants (on a 1:1 basis) issued to him on preferential basis by the Board of Directors on March 03, 2026.

6.	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	Yes. The allottee belongs to the Promoter of the Company and therefore the transaction qualifies as a related party transaction. The transaction has been carried out pursuant to Special Resolution passed by the Shareholders of M/s. Virinchi Limited, through postal ballot on February 23, 2026.
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not Applicable – There is no sale/lease/disposal of undertaking. The change in subsidiary status occurred solely due to allotment of equity shares to the Promoter upon conversion of convertible equity warrants by the subsidiary company.
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable.